ID: h-c32ed9ee29
Hypothesis
Microglial Reactivation Status Modifies Amyloid Clearance and p-tau217 Normalization Relationship
Donanemab triggers acute microglial activation (ARIA-E).
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 7 support✗ 2 oppose
🧪 Overview
Donanemab triggers acute microglial activation (ARIA-E). Patients achieving favorable M2-like phenotype show better p-tau217 normalization due to enhanced tau aggregate clearance, while persistent M1 phenotype may show biomarker dissociation. However, TSPO-PET M1/M2 specificity in humans is questionable—human microglia do not conform cleanly to the rodent M1/M2 dichotomy, and TSPO signals are non-specific for activation state.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
B["TREM2 Receptor<br/>Ligand Binding"]
C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
D["SYK Kinase<br/>Activation"]
E["PLCG2<br/>IP3 + DAG Generation"]
F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
G["Microglial Phagocytosis<br/>Plaque Compaction"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Donanemab-treated patients show acute TSPO-PET increases suggesting microglial activation
Supports
The dual role of microglia in Alzheimer's disease: from immune regulation to pathological progression.
Supports
Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.
Supports
CD11c+ microglia: From basic research to clinical application.
Supports
Microglia Demonstrate Local Mixed Inflammation and a Defined Morphological Shift in an APP/PS1 Mouse Model.
Supports
A ligand-mimetic anti-TREM2 agonist antibody elevates soluble TREM2 and ameliorates pathology in mouse models of Alzheimer's disease and multiple sclerosis.
Contradicts
Human microglia do not conform cleanly to the M1/M2 dichotomy established in rodent models
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Medium
0.0227
Events (7d)
1
Price History
▲0.6%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF individuals with TREM2 R47H variant (risk genotype) and individuals with reference alleles are treated with donanemab, THEN the TREM2 R47H group will demonstrate attenuated p-tau217 reduction relat | TREM2 R47H carriers will show ≥30% less p-tau217 normalization per unit reduction in amyloid PET SUVr compared to reference allele carriers | — no observation — | pending | 0.65 |
| IF patients receiving donanemab are stratified by baseline TSPO-PET signal into high vs low microglial activation tertiles, THEN the high activation tertile will demonstrate a divergent p-tau217 traje | High TSPO-PET tertile will show ≥40% greater variance in p-tau217 reduction per unit amyloid clearance compared to low tertile, indicating biomarker dissociatio | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF individuals with TREM2 R47H variant (risk genotype) and individuals with reference alleles are treated with donanemab, THEN the TREM2 R47H group will demonstrate attenuated p-tau217 reduction relative to their degree of amyloid clearance compared to the reference group, within 12 months of treatm
Predicted outcome: TREM2 R47H carriers will show ≥30% less p-tau217 normalization per unit reduction in amyloid PET SUVr compared to reference allele carriers
Falsification: TREM2 R47H carriers show equal or greater p-tau217 normalization relative to amyloid clearance, indicating microglial genotype does not modify the amyloid-tau biomarker relationship
pendingconf 55%
IF patients receiving donanemab are stratified by baseline TSPO-PET signal into high vs low microglial activation tertiles, THEN the high activation tertile will demonstrate a divergent p-tau217 trajectory relative to amyloid clearance compared to the low activation tertile (dissociation pattern), w
Predicted outcome: High TSPO-PET tertile will show ≥40% greater variance in p-tau217 reduction per unit amyloid clearance compared to low tertile, indicating biomarker d
Falsification: High and low TSPO-PET tertiles show parallel p-tau217 normalization relative to amyloid clearance (similar slope), indicating TSPO-PET does not capture functional microglial states relevant to tau dyn
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.